Literature DB >> 22875741

Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.

Maryam Karimi Khaledi1, Katie J Suda, Chasity M Shelton.   

Abstract

CASE: The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.
CONCLUSION: Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875741     DOI: 10.1007/s11096-012-9685-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  11 in total

Review 1.  The Mount Sinai conference on the pharmacotherapy of schizophrenia.

Authors:  Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; John M Davis; John M Kane; Jeffrey Lieberman; Nina R Schooler
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

2.  Metoclopramide, an increasingly recognized cause of tardive dyskinesia.

Authors:  Christopher Kenney; Christine Hunter; Anthony Davidson; Joseph Jankovic
Journal:  J Clin Pharmacol       Date:  2008-01-25       Impact factor: 3.126

Review 3.  Review article: metoclopramide and tardive dyskinesia.

Authors:  A S Rao; M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

4.  Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

Authors:  Stefan Leucht; Gabi Pitschel-Walz; Rolf R Engel; Werner Kissling
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Ten-year outcome of tardive dyskinesia.

Authors:  G Gardos; D E Casey; J O Cole; A Perenyi; E Kocsis; M Arato; J A Samson; C Conley
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

7.  Adverse neurologic effects of metoclopramide.

Authors:  J D Grimes; M N Hassan; D N Preston
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

8.  Prospective study of tardive dyskinesia in the elderly: rates and risk factors.

Authors:  M G Woerner; J M Alvir; B L Saltz; J A Lieberman; J M Kane
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

Review 9.  Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.

Authors:  L G Miller; J Jankovic
Journal:  Arch Intern Med       Date:  1989-11

10.  Tardive dyskinesia associated with use of metoclopramide in a child.

Authors:  P E Putnam; S R Orenstein; H B Wessel; R M Stowe
Journal:  J Pediatr       Date:  1992-12       Impact factor: 4.406

View more
  3 in total

1.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

Review 2.  The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

Authors:  Melissa Lau Moon Lin; Paula D Robinson; Jacqueline Flank; Lillian Sung; L Lee Dupuis
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

3.  Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List.

Authors:  Rachel S Meyers; Jennifer Thackray; Kelly L Matson; Christopher McPherson; Lisa Lubsch; Robert C Hellinga; David S Hoff
Journal:  J Pediatr Pharmacol Ther       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.